

Immuno-Oncology: A Renaissance in the Treatment of Lung Cancer

Scientific Symposium
Sponsored by MSD

Wednesday, 7 December 2016
12:45 – 14:15

This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.

Messe Wien Exhibition & Congress Center
Room: Lehar 3 & 4
Vienna, Austria

CHAIR

David Carbone

Barbara J. Bonner Chair in Lung Cancer Research
President, International Association for the Study of Lung Cancer (IASLC)
Professor of Medicine
Director, James Thoracic Oncology Center
Columbus, Ohio, USA

FACULTY

Thomas Newsom-Davis

Consultant Medical Oncologist
Chelsea and Westminster Hospital
Foundation NHS Trust
London, United Kingdom

Keith Kerr

Consultant Pathologist, Department of Pathology
Aberdeen Royal Infirmary
Professor of Pulmonary Pathology
Aberdeen University Medical School
Aberdeen, Scotland, United Kingdom

Naiyer A. Rizvi

Professor of Medicine
Director of Thoracic Oncology and Phase I Immunotherapeutics
Columbia University Medical Center
New York, New York, USA

Educational Objectives

- Establish an understanding of the mechanism of disease in lung cancer and the rationale for checkpoint inhibitors as a treatment option
- Share the experience on the use of immunotherapy in cancer and the unique response patterns associated with treatment in Lung Cancer
- Educate on biomarkers and their role in guiding treatment decisions

Chair: David Carbone (USA)

AGENDA

12:45 – 12:50	Welcome and Opening Remarks	David Carbone
12:50 – 13:05	Immunotherapy Experience in Lung Cancer	Naiyer Rizvi
13:05 – 13:20	The Value of Biomarkers in Lung Cancer	Keith Kerr
13:20 – 13:35	Patient Management	Thomas Newsom-Davis
13:35 – 13:50	Lung Cancer Landscape: Future Directions	David Carbone
13:50 – 14:15	Panel Discussion	Faculty
14:15	Closing Remarks	David Carbone